Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Riccardin D, a drug candidate, inhibits gastric cancer progression by targeting RAD54L

Qi Pan, Weimin Zhu, Pei Xiang

Department of Oncology, Wuxi No. 2 Chinese Medicine Hospital, Wuxi, Jiangsu Province 214000, China;

For correspondence:- Pei Xiang Email: p_xiang1635@163.com Tel:+8651085061407

Accepted: 23 December 2022 Published: 30 January 2023

Citation: Pan Q, Zhu W, Xiang P. Riccardin D, a drug candidate, inhibits gastric cancer progression by targeting RAD54L. Trop J Pharm Res 2023; 22(1):81-87 doi: 10.4314/tjpr.v22i1.12

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the beneficial function of RAD54L in gastric cancer.

Methods: Batch correction, metaboanalyst, volcano plot and heatmap were used for analyzing different expression genes. Metascape and strings were used for functional enrichment and protein-protein interaction network analysis, respectively. expression of RAD54L was analyzed using online platform-timer, ualcan and GEPIA. Correlation between RAD54L and poor prognosis was analyzed using Kaplan-Meier curve. expression of RAD54L was evaluated by Real Time-quantitative PCR and western blotting, while cell proliferation, cell apoptosis and cell cycle were determined by CCK8 and flow cytometry, respectively.

Results: A total of 57 upregulated DEGs and 33 downregulated DEGs were involved in gastric cancer. Among these, RAD54L was a hub gene which is highly expressed, and is related to poor survival in gastric cancer. Moreover, knockdown of RAD54L inhibited cell viability and facilitated cell apoptosis in gastric cancer cells (p < 0.05). On the other hand, overexpression of RAD54L promoted cell proliferation and reduced cell apoptosis in gastric cancer (p < 0.05). In addition, RAD54L positively regulated cell cycle in gastric cancer cell lines. Furthermore, riccardin D negatively regulated cell cycle in gastric cancer cell lines by targeting RAD54L.

Conclusion: Riccardin DRAD54L is a potential drug for the treatment of gastric cancer. However, developmental work, including in vivo studies, are required to ascertain this.

Keywords: Riccardin, RAD54L, Gastric carcinoma, Tumor progression, Cell apoptosis, Poor prognosis